MorphoSys AG

XTRA:MOR Stock Report

Market Cap: €2.5b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

MorphoSys Valuation

Is MOR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MOR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MOR's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MOR's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MOR?

Key metric: As MOR is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for MOR. This is calculated by dividing MOR's market cap by their current revenue.
What is MOR's PS Ratio?
PS Ratio10.5x
Sales€241.47m
Market Cap€2.53b

Price to Sales Ratio vs Peers

How does MOR's PS Ratio compare to its peers?

The above table shows the PS ratio for MOR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7.6x
BIO3 Biotest
1.5x3.6%€1.4b
FYB Formycon
13.6x33.4%€827.2m
HPHA Heidelberg Pharma
12.3x16.6%€103.9m
MDG1 Medigene
3x16.1%€22.6m
MOR MorphoSys
10.5x25.0%€2.5b

Price-To-Sales vs Peers: MOR is expensive based on its Price-To-Sales Ratio (10.5x) compared to the peer average (7.7x).

Price to Sales Ratio vs Industry

How does MOR's PS Ratio compare vs other companies in the DE Biotechs Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
PA8 Paion
0.2x30.2%US$2.78m
V9Z Aceragen
0.3x-161.8%US$2.18m
MOR 10.5xIndustry Avg. 7.9xNo. of Companies6PS0612182430+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: MOR is expensive based on its Price-To-Sales Ratio (10.5x) compared to the European Biotechs industry average (9.5x).

Price to Sales Ratio vs Fair Ratio

What is MOR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MOR PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio10.5x
Fair PS Ratio7x

Price-To-Sales vs Fair Ratio: MOR is expensive based on its Price-To-Sales Ratio (10.5x) compared to the estimated Fair Price-To-Sales Ratio (7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MOR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
€63.33
0%
16.5%€68.00€40.00n/a6
Nov ’25n/a
€63.33
0%
16.5%€68.00€40.00n/a6
Oct ’25n/a
€63.33
0%
16.5%€68.00€40.00n/a6
Sep ’25n/a
€63.33
0%
16.5%€68.00€40.00n/a6
Aug ’25€67.70
€58.71
-13.3%
25.3%€68.00€31.00n/a7
Jul ’25€67.60
€58.71
-13.1%
25.3%€68.00€31.00n/a7
Jun ’25€68.65
€58.71
-14.5%
25.3%€68.00€31.00n/a7
May ’25€66.20
€58.71
-11.3%
25.3%€68.00€31.00n/a7
Apr ’25€67.20
€58.71
-12.6%
25.3%€68.00€31.00n/a7
Mar ’25€65.50
€50.38
-23.1%
36.4%€68.00€22.00n/a8
Feb ’25€40.62
€31.35
-22.8%
33.5%€47.00€15.00n/a10
Jan ’25€34.00
€31.00
-8.8%
33.6%€47.00€15.00n/a10
Dec ’24€24.44
€31.13
+27.4%
33.3%€47.00€15.00n/a8
Nov ’24€31.29
€34.33
+9.7%
17.8%€45.00€25.00n/a9
Oct ’24€25.83
€31.61
+22.4%
29.1%€45.00€13.50n/a9
Sep ’24€27.89
€27.94
+0.2%
38.9%€45.00€12.50n/a8
Aug ’24€27.00
€28.19
+4.4%
40.0%€47.00€12.50€67.708
Jul ’24€27.23
€25.56
-6.1%
50.9%€47.00€12.50€67.608
Jun ’24€23.80
€23.06
-3.1%
59.3%€47.00€12.00€68.658
May ’24€19.06
€18.31
-3.9%
58.8%€42.00€11.00€66.208
Apr ’24€14.65
€18.31
+25.0%
58.8%€42.00€11.00€67.208
Mar ’24€17.21
€18.25
+6.0%
59.2%€42.00€11.00€65.508
Feb ’24€18.45
€23.44
+27.1%
76.2%€65.00€11.00€40.629
Jan ’24€13.21
€25.06
+89.7%
67.8%€65.00€12.00€34.009
Dec ’23€15.53
€29.11
+87.5%
60.9%€65.00€13.00€24.449
Nov ’23€19.72
€35.61
+80.6%
39.6%€65.00€18.00€31.299

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

Amneal Pharmaceuticals

US$2.6b

Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.

2DT

US$7.70

7D

-4.3%

1Y

91.5%

Teva Pharmaceutical Industries

US$19.4b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEV

US$16.25

7D

2.5%

1Y

89.8%

Merck

US$252.6b

Operates as a healthcare company worldwide.

6MK

US$97.10

7D

6.7%

1Y

3.9%